| Literature DB >> 26217284 |
Tom J Barry1, Bram Vervliet1, Dirk Hermans1.
Abstract
Models of exposure therapy, one of the key components of cognitive behavioral therapy for anxiety disorders, suggest that attention may play an important role in the extinction of fear and anxiety. Evidence from cognitive research suggests that individual differences may play a causal role in the onset and maintenance of anxiety disorders and so it is also likely to influence treatment. We review the evidence concerning attention and treatment outcomes in anxiety disorders. The evidence reviewed here suggests that that attention biases assessed at pre-treatment might actually predict improved response to treatment, and in particular that prolonged engagement with threat as measured in tasks such as the dot probe is associated with greater reductions in anxious symptoms following treatment. We examine this research within a fear learning framework, considering the possible role of individual differences in attention in the extinction of fear during exposure. Theoretical, experimental and clinical implications are discussed, particularly with reference to the potential for attention bias modification programs in augmenting treatment, and also with reference to how existing research in this area might inform best practice for clinicians.Entities:
Keywords: anxiety; attention; exposure; fear; phobia; treatment
Year: 2015 PMID: 26217284 PMCID: PMC4495309 DOI: 10.3389/fpsyg.2015.00968
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
A summary of research exploring the relationship between pre-treatment attentional bias and treatment outcomes following CBT for a range of anxiety disorders.
| Sample | Measures | Treatment | Main findings | |||
|---|---|---|---|---|---|---|
| Attention | Outcomes | Conditions | No. sessions | |||
| Adults; SP (Spiders); | Stroop | Behavioral approach test (BAT) | Exposure with or without elaboration | 1 | Worse outcomes for people with SI | |
| Adults; SAD; | Stroop | Clinician severity rating (CSR) | Drug vs. CBT vs. placebo | 12 | No significant effects | |
| Adults; SP (Spiders); | Stroop | Symptom scale (SPQ); BAT | Exposure alone | 1 | No significant effects | |
| Adults; SAD; | Stroop | Diagnostic interview (ADIS) | Individual, group or self-administered CBT | 12 or 3 months with manual | Treatment responders more likely to show SI | |
| Adults; PTSD; | Stroop | Symptom scale (CAPS) | CBT vs. group support vs. wait-list | 8–12 | No significant effects | |
| Children; mixed; | Dot Probe | Diagnostic interview (ADIS-C) | Individual (69%) or group (31%) CBT | Not given | Treatment responders attend | |
| Children; mixed | Dot Probe | Diagnostic interview (ADIS-C) | Phase 1: individual CBT Phase 2: parent–child CBT for phase 1 non-responders | 10 in phase 1; 4 in phase 2 | Initial responders attend | |
| Adults; SAD; | Dot Probe | Self-report symptom scale (LSAS) | CBT with virtual exposure | 8 | Symptom reduction associated with attention | |
| Children; GAD/SAD; | Dot Probe | Self-report symptom scale (SCAS-P); ADIS-C | Group CBT | 10 | Symptom reduction associated with attention | |
| Adults; SAD; | Spatial cuing | Clinician rated fear and avoidance; LSAS, SIAS, and SPS composite | CBT vs. ACT | 12 | Symptom reduction associated with attention | |